FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225550198> ?p ?o ?g. }

• W4225550198 endingPage "989" @default.
• W4225550198 startingPage "981" @default.
• W4225550198 abstract "Cranial dural arteriovenous fistulas (dAVFs) are often treated with endovascular therapy, but occasionally a multimodality approach including surgery and/or radiosurgery is utilized. Recurrence after an initial angiographic cure has been reported, with estimated rates ranging from 2% to 14.3%, but few risk factors have been identified. The objective of this study was to identify risk factors associated with recurrence of dAVF after putative cure.The Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR) data were retrospectively reviewed. All patients with angiographic cure after treatment and subsequent angiographic follow-up were included. The primary outcome was recurrence, with risk factor analysis. Secondary outcomes included clinical outcomes, morbidity, and mortality associated with recurrence. Risk factor analysis was performed comparing the group of patients who experienced recurrence with those with durable cure (regardless of multiple recurrences). Time-to-event analysis was performed using all collective recurrence events (multiple per patients in some cases).Of the 1077 patients included in the primary CONDOR data set, 457 met inclusion criteria. A total of 32 patients (7%) experienced 34 events of recurrence at a mean of 368.7 days (median 192 days). The recurrence rate was 4.5% overall. Kaplan-Meier analysis predicted long-term recurrence rates approaching 11% at 3 years. Grade III dAVFs treated with endovascular therapy were statistically significantly more likely to experience recurrence than those treated surgically (13.3% vs 0%, p = 0.0001). Tentorial location, cortical venous drainage, and deep cerebral venous drainage were all risk factors for recurrence. Endovascular intervention and radiosurgery were associated with recurrence. Six recurrences were symptomatic, including 2 with hemorrhage, 3 with nonhemorrhagic neurological deficit, and 1 with progressive flow-related symptoms (decreased vision).Recurrence of dAVFs after putative cure can occur after endovascular treatment. Risk factors include tentorial location, cortical venous drainage, and deep cerebral drainage. Multimodality therapy can be used to achieve cure after recurrence. A delayed long-term angiographic evaluation (at least 1 year from cure) may be warranted, especially in cases with risk factors for recurrence." @default.
• W4225550198 created "2022-05-05" @default.
• W4225550198 creator A5010496038 @default.
• W4225550198 creator A5013652245 @default.
• W4225550198 creator A5015329897 @default.
• W4225550198 creator A5020200536 @default.
• W4225550198 creator A5023364250 @default.
• W4225550198 creator A5029613368 @default.
• W4225550198 creator A5034637646 @default.
• W4225550198 creator A5035302435 @default.
• W4225550198 creator A5037307510 @default.
• W4225550198 creator A5037367242 @default.
• W4225550198 creator A5038571038 @default.
• W4225550198 creator A5038924268 @default.
• W4225550198 creator A5040105263 @default.
• W4225550198 creator A5043226851 @default.
• W4225550198 creator A5043879863 @default.
• W4225550198 creator A5051773233 @default.
• W4225550198 creator A5053752894 @default.
• W4225550198 creator A5057368505 @default.
• W4225550198 creator A5057716113 @default.
• W4225550198 creator A5058905474 @default.
• W4225550198 creator A5059303705 @default.
• W4225550198 creator A5062397023 @default.
• W4225550198 creator A5066810919 @default.
• W4225550198 creator A5068016958 @default.
• W4225550198 creator A5068894728 @default.
• W4225550198 creator A5070057851 @default.
• W4225550198 creator A5070619742 @default.
• W4225550198 creator A5075287421 @default.
• W4225550198 creator A5078938709 @default.
• W4225550198 creator A5080595395 @default.
• W4225550198 creator A5085188789 @default.
• W4225550198 creator A5091571323 @default.
• W4225550198 date "2022-04-01" @default.
• W4225550198 modified "2023-10-14" @default.
• W4225550198 title "Recurrence after cure in cranial dural arteriovenous fistulas: a collaborative effort by the Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR)" @default.
• W4225550198 cites W1980741434 @default.
• W4225550198 cites W1998427230 @default.
• W4225550198 cites W2097420979 @default.
• W4225550198 cites W2125732013 @default.
• W4225550198 cites W2735897814 @default.
• W4225550198 cites W2895797737 @default.
• W4225550198 doi "https://doi.org/10.3171/2021.1.jns202033" @default.
• W4225550198 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34507283" @default.
• W4225550198 hasPublicationYear "2022" @default.
• W4225550198 type Work @default.
• W4225550198 citedByCount "5" @default.
• W4225550198 countsByYear W42255501982022 @default.
• W4225550198 countsByYear W42255501982023 @default.
• W4225550198 crossrefType "journal-article" @default.
• W4225550198 hasAuthorship W4225550198A5010496038 @default.
• W4225550198 hasAuthorship W4225550198A5013652245 @default.
• W4225550198 hasAuthorship W4225550198A5015329897 @default.
• W4225550198 hasAuthorship W4225550198A5020200536 @default.
• W4225550198 hasAuthorship W4225550198A5023364250 @default.
• W4225550198 hasAuthorship W4225550198A5029613368 @default.
• W4225550198 hasAuthorship W4225550198A5034637646 @default.
• W4225550198 hasAuthorship W4225550198A5035302435 @default.
• W4225550198 hasAuthorship W4225550198A5037307510 @default.
• W4225550198 hasAuthorship W4225550198A5037367242 @default.
• W4225550198 hasAuthorship W4225550198A5038571038 @default.
• W4225550198 hasAuthorship W4225550198A5038924268 @default.
• W4225550198 hasAuthorship W4225550198A5040105263 @default.
• W4225550198 hasAuthorship W4225550198A5043226851 @default.
• W4225550198 hasAuthorship W4225550198A5043879863 @default.
• W4225550198 hasAuthorship W4225550198A5051773233 @default.
• W4225550198 hasAuthorship W4225550198A5053752894 @default.
• W4225550198 hasAuthorship W4225550198A5057368505 @default.
• W4225550198 hasAuthorship W4225550198A5057716113 @default.
• W4225550198 hasAuthorship W4225550198A5058905474 @default.
• W4225550198 hasAuthorship W4225550198A5059303705 @default.
• W4225550198 hasAuthorship W4225550198A5062397023 @default.
• W4225550198 hasAuthorship W4225550198A5066810919 @default.
• W4225550198 hasAuthorship W4225550198A5068016958 @default.
• W4225550198 hasAuthorship W4225550198A5068894728 @default.
• W4225550198 hasAuthorship W4225550198A5070057851 @default.
• W4225550198 hasAuthorship W4225550198A5070619742 @default.
• W4225550198 hasAuthorship W4225550198A5075287421 @default.
• W4225550198 hasAuthorship W4225550198A5078938709 @default.
• W4225550198 hasAuthorship W4225550198A5080595395 @default.
• W4225550198 hasAuthorship W4225550198A5085188789 @default.
• W4225550198 hasAuthorship W4225550198A5091571323 @default.
• W4225550198 hasBestOaLocation W42255501982 @default.
• W4225550198 hasConcept C126838900 @default.
• W4225550198 hasConcept C141071460 @default.
• W4225550198 hasConcept C167135981 @default.
• W4225550198 hasConcept C2776341189 @default.
• W4225550198 hasConcept C2779063477 @default.
• W4225550198 hasConcept C2779603958 @default.
• W4225550198 hasConcept C2780387249 @default.
• W4225550198 hasConcept C509974204 @default.
• W4225550198 hasConcept C71924100 @default.
• W4225550198 hasConceptScore W4225550198C126838900 @default.
• W4225550198 hasConceptScore W4225550198C141071460 @default.
• W4225550198 hasConceptScore W4225550198C167135981 @default.
• W4225550198 hasConceptScore W4225550198C2776341189 @default.
• W4225550198 hasConceptScore W4225550198C2779063477 @default.

• next